Floatz logo

Evomela

Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

M.D. Anderson Cancer CenterPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor cohort.

Asset / SponsorPhaseRating
Cixutumumab
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
Gradalis, Inc.
Phase 3BB
Irinotecan
Gradalis, Inc.
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2B

View all 36 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →